---
schema_version: "secwatch.filing_event.v1"
accession: "0001831868-25-000006"
form_type: "8-K"
ticker: "ICU"
cik: "0001831868"
company_name: "SeaStar Medical Holding Corp"
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:59:18.576239+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# SeaStar Medical Q2 net loss $2.0M; NEUTRALIZE-AKI trial over 60% enrolled

## Summary
- Net revenue $0.3M from QUELIMMUNE sales; net loss $2.0M ($0.18/share) vs $3.2M loss year ago.
- NEUTRALIZE-AKI trial enrolled 125 of 200 patients; interim DSMB recommendations expected Q3 2025.
- Three new children's hospitals adopted QUELIMMUNE; SAVE registry shows 75% 28-day survival in 20 pediatric patients.
- Raised $12.4M in June and $8.4M in two July/August 2025 offerings; cash at June 30 was $6.3M.
- CMS agreed to cover clinical trial expenses for NEUTRALIZE-CRS; DoD awarded $2M grant for burn research.

## SEC filing metadata
- accession: 0001831868-25-000006
- form_type: 8-K
- ticker: ICU
- cik: 0001831868
- company_name: SeaStar Medical Holding Corp
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831868/000183186825000006/0001831868-25-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831868/000183186825000006/icu-20250813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001831868-25-000006
- JSON: https://secwatch.observer/filing/0001831868-25-000006.json
- Plain text: https://secwatch.observer/filing/0001831868-25-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.